Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mi-Gel for entry dyspareunia
ACTRN12624001210561Phase 3Completed
- Sponsor
- TA Pharma
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amitriptyline + estriol, amitriptyline and estriol in dyspareunia and vulvodynia (2 arms), sponsored by TA Pharma. Primary endpoint: Change from baseline in weekly pain scores at Week 12. Started Feb 2025; status: completed.
02
Drugs
amitriptyline + estriolamitriptylineestriol
03
Conditions
dyspareuniavulvodynia
Beyond the preview
Go deeper on ACTRN12624001210561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001210561.